The RATIFY study was a global, randomized phase III study that randomized 717 adults <60 years of age with newly diagnosed FLT3-mutated AML (either ITD or TKD) to standard chemotherapy (i.e. induction with “7 + 3” chemotherapy and high-dose cytarabine consolidation) plus either midostaurin (50 mg orally twice daily) or placebo. The gene discussed is FLT3; the disease is acute myeloid leukemia.